Everest Organics Quarterly Results for Trading Insights
In 2026, Everest Organics (EVERESTO) reported revenue ₹190 Cr and net profit ₹6 Cr. For annual financials, live price and key ratios, visit EVERESTO share price.
EVERESTO Quarterly Results — Revenue, Profit & EPS Highlights
Everest Organics latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore EVERESTO share price history to track price trends across different timeframes.
- Revenue of ₹160 Cr in March 2025 (+0.0% vs March 2025, -19.2% vs March 2024)
- Net Profit of ₹-1 Cr in March 2025 (+0.0% vs March 2025)
- EBITDA of ₹8 Cr in March 2025 (+0.0% vs March 2025)
- Operating Margin of 5.0% in March 2025 (+0.0pp vs March 2025)
- Earnings Per Share of ₹-2.97 in March 2025 (+0.0% vs March 2025)
Everest Organics Quarterly Results — Revenue, EBITDA, Net Profit & EPS
EVERESTO quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | 2026 | March 2025 | March 2024 | March 2023 | March 2022 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 190 | 160 | 198 | 190 | 202 | 18.8% | - |
| Net Profit (₹ Cr) | 6 | -1 | 0 | 0 | 1 | - | - |
| EBITDA (₹ Cr) | 18 | 8 | 12 | 8 | 9 | - | - |
| EPS (₹) | 6.00 | -2.97 | 0.17 | -0.23 | 1.43 | - | - |
| Operating Margin (%) | 9.0% | 5.0% | 6.0% | 1.0% | 3.0% | - | - |
EVERESTO Share Price Trend — 1-Year Movement Across Quarterly Results
Everest Organics 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with EVERESTO stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
EVERESTO vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Everest Organics latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹443,373.10 Cr | 1824.8 | 14,875 | 3,125 | +10.8% | - | 21.0% | 140.4 |
|
Divis Laboratories
Sept 2025 |
₹178,235.60 Cr | 6796.0 | 2,860 | 689 | +7.1% | - | 24.1% | 261.7 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹145,389.39 Cr | 4295.8 | 3,219 | 591 | +11.3% | - | 18.4% | 244.9 |
|
Cipla
Mar 2026 |
₹107,240.96 Cr | 1327.6 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 193.2 |
|
Dr Reddys Laborator…
Mar 2026 |
₹105,607.38 Cr | 1265.3 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 477.5 |
All amounts in ₹ Crores